Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial

Authors: Gerd R Burmester, Joel M. Kremer, Filip Van den Bosch, Alan Kivitz, Louis Bessette, Yihan Li, Yijie Zhou, Mohamed I. A. Othman, Aileen L. Pangan, Heidi S. Camp - The Lancet 2018 cited by 397